RxDoctor Payments DataLook up a doctor →

William Greisner, MD

Allergy & Immunology · Lexington, KYNPI 1720095334

Payments from drug & device makers

$1,800,823in general payments, 2019–2025

Across 927 payments — averaging $1942.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$737K
  • Novartis$257K
  • GSK$196K
  • Regeneron$136K
  • Teva Pharmaceuticals USA, Inc.$135K
  • Pfizer$108K
  • plus $233K from 37 others

What the payments were for

  • Consulting fees$18,23746%
  • Speaking & faculty fees$1,3253%
  • Travel & lodging$1,3483%
  • Food & beverage$18,20546%
  • Education$2241%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,800,823 in reported general payments places this provider in the 95th percentile of 66 allergy & immunology providers in Kentucky.

See all allergy & immunology providers in Kentucky

Medicare billing

Part B allowed, 2024
$75,478
Medicare patients
183
Services billed
5,357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab23$62,685
Trelegy ElliptaFluticasone/Umeclidin/Vilanter62$48,377
CuvitruImmun Glob G(Igg)/Gly/Iga Ov5023$40,284
SymbicortBudesonide/Formoterol Fumarate80$25,985
Breo ElliptaFluticasone/Vilanterol53$25,401
Spiriva RespimatTiotropium Bromide32$20,873
Advair HfaFluticasone Propion/Salmeterol21$11,790
Fluticasone-SalmeterolFluticasone Propion/Salmeterol59$10,335
Epinephrine34$8,851
Qvar RedihalerBeclomethasone Dipropionate16$6,769
Azelastine Hcl175$4,658
Fluticasone Propionate HfaFluticasone Propionate11$4,338
Wixela InhubFluticasone Propion/Salmeterol45$3,377
Albuterol Sulfate HfaAlbuterol Sulfate90$3,332
Arnuity ElliptaFluticasone Furoate13$3,248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$195,733$77,026128 claims
Genentech, Inc.Xolair$162$62,68523 claims
Takeda Pharmaceuticals U.S.A., Inc.Cuvitru$588$40,28423 claims
AstraZenecaSymbicort$736,972$25,98580 claims
Boehringer IngelheimSpiriva Respimat$126$20,87332 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$134,807$6,76916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 66 allergy & immunology providers in Kentucky.

Other allergy & immunology in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →